$XOMA
XOMA Royalty Corp

2018 Q1 Form 10-Q Financial Statement

#000156459018012453 Filed on May 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1 2016 Q4
Revenue $463.0K $260.0K $524.0K
YoY Change 78.08% -93.44% -98.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.170M $5.170M $5.180M
YoY Change 0.0% 20.09% 9.98%
% of Gross Profit
Research & Development $432.0K $3.993M $8.250M
YoY Change -89.18% -70.66% -39.34%
% of Gross Profit
Depreciation & Amortization $10.00K $150.0K $170.0K
YoY Change -93.33% -30.23% -19.05%
% of Gross Profit
Operating Expenses $5.600M $9.160M $13.43M
YoY Change -38.86% -48.87% -26.62%
Operating Profit -$5.137M -$10.92M -$17.46M
YoY Change -52.96% -21.94% -160.75%
Interest Expense -$170.0K -$610.0K -$960.0K
YoY Change -72.13% -39.0% 57.38%
% of Operating Profit
Other Income/Expense, Net $1.331M $205.0K -$21.00K
YoY Change 549.27% -96.35% -99.38%
Pretax Income -$3.806M -$10.72M -$17.48M
YoY Change -64.48% 28.02% -168.95%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.806M -$10.72M -$17.48M
YoY Change -64.48% 28.09% -168.95%
Net Earnings / Revenue -822.03% -4121.15% -3335.88%
Basic Earnings Per Share -$0.46 -$2.37 -$2.89
Diluted Earnings Per Share -$0.46 -$2.37 -$2.89
COMMON SHARES
Basic Shares Outstanding 8.313M 6.047M
Diluted Shares Outstanding 8.313M

Balance Sheet

Concept 2018 Q1 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.00M $20.00M $25.74M
YoY Change 110.0% -57.13% -61.15%
Cash & Equivalents $42.00M $20.05M $25.74M
Short-Term Investments $0.00
Other Short-Term Assets $300.0K $300.0K $900.0K
YoY Change 0.0% -81.25% -52.63%
Inventory
Prepaid Expenses
Receivables $400.0K $1.300M $474.0K
Other Receivables $0.00 $0.00 $92.00K
Total Short-Term Assets $42.70M $21.70M $27.16M
YoY Change 96.77% -56.77% -62.39%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $400.0K $1.036M
YoY Change -75.0% -77.78% -48.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K $500.0K $481.0K
YoY Change 20.0% -28.57% -27.56%
Total Long-Term Assets $600.0K $800.0K $1.517M
YoY Change -25.0% -66.67% -42.99%
TOTAL ASSETS
Total Short-Term Assets $42.70M $21.70M $27.16M
Total Long-Term Assets $600.0K $800.0K $1.517M
Total Assets $43.30M $22.50M $28.68M
YoY Change 92.44% -57.22% -61.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $4.200M $5.689M
YoY Change -66.67% -8.7% -16.72%
Accrued Expenses $600.0K $4.100M $8.100M
YoY Change -85.37% 2.5% 9.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.50M $17.86M
YoY Change 22.55% 202.12%
Total Short-Term Liabilities $5.900M $22.20M $32.51M
YoY Change -73.42% 8.29% 39.54%
LONG-TERM LIABILITIES
Long-Term Debt $14.60M $14.10M $25.31M
YoY Change 3.55% -60.83% -40.8%
Other Long-Term Liabilities $17.20M $17.40M $69.00K
YoY Change -1.15% 370.27% -89.75%
Total Long-Term Liabilities $31.80M $31.50M $25.38M
YoY Change 0.95% -20.65% -41.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.900M $22.20M $32.51M
Total Long-Term Liabilities $31.80M $31.50M $25.38M
Total Liabilities $37.70M $53.70M $75.89M
YoY Change -29.8% -10.65% -1.69%
SHAREHOLDERS EQUITY
Retained Earnings -$1.194B
YoY Change 4.7%
Common Stock $1.146B
YoY Change 0.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.637M -$31.20M -$47.21M
YoY Change
Total Liabilities & Shareholders Equity $43.30M $22.50M $28.68M
YoY Change 92.44% -57.22% -61.7%

Cashflow Statement

Concept 2018 Q1 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$3.806M -$10.72M -$17.48M
YoY Change -64.48% 28.09% -168.95%
Depreciation, Depletion And Amortization $10.00K $150.0K $170.0K
YoY Change -93.33% -30.23% -19.05%
Cash From Operating Activities -$3.839M -$14.35M $7.000M
YoY Change -73.25% -11.91% -75.67%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K
YoY Change -175.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $810.0K $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $810.0K -$30.00K
YoY Change -100.0% -2800.0% -100.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.309M $5.380M
YoY Change -57.08%
Debt Paid & Issued, Net $16.38M
YoY Change 400.76%
Cash From Financing Activities 2.316M 7.870M -1.840M
YoY Change -70.57% -338.48% -2400.0%
NET CHANGE
Cash From Operating Activities -3.839M -14.35M 7.000M
Cash From Investing Activities 0.000 810.0K -30.00K
Cash From Financing Activities 2.316M 7.870M -1.840M
Net Change In Cash -1.523M -5.670M 5.130M
YoY Change -73.14% -71.1% -84.8%
FREE CASH FLOW
Cash From Operating Activities -$3.839M -$14.35M $7.000M
Capital Expenditures -$30.00K
Free Cash Flow $7.030M
YoY Change -75.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1666000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1000000
CY2018Q1 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
20000
CY2018Q1 us-gaap Contracts Revenue
ContractsRevenue
401000
CY2017Q1 us-gaap Contracts Revenue
ContractsRevenue
150000
CY2018Q1 xoma Revenue Recognize Under Units Of Revenue Method
RevenueRecognizeUnderUnitsOfRevenueMethod
62000
CY2017Q1 xoma Revenue Recognize Under Units Of Revenue Method
RevenueRecognizeUnderUnitsOfRevenueMethod
110000
CY2018Q1 us-gaap Revenues
Revenues
463000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
432000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5168000
CY2017Q1 us-gaap Restructuring Charges
RestructuringCharges
2020000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
5600000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
11180000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5137000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10920000
CY2018Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
170000
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
609000
CY2017Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-515000
CY2018Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1501000
CY2017Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1329000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3806000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-10715000
CY2017Q1 xoma Deemed Dividends On Convertible Preferred Stock
DeemedDividendsOnConvertiblePreferredStock
5603000
CY2018Q1 xoma Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3806000
CY2017Q1 xoma Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-16318000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1416000
CY2017Q1 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
506000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
147000
CY2017Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
286000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-261000
CY2017Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1314000
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
21000
CY2017Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-55000
CY2018Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
39000
CY2017Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-33000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-53000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-345000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1593000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5281000
CY2018Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
138000
CY2017Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-76000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-62000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-110000
CY2018Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
29000
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
18000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3839000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14348000
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
813000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
813000
CY2017Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
20072000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2309000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5380000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
CY2017Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
16380000
CY2017Q1 xoma End Of Term Fee Paid To Lender
EndOfTermFeePaidToLender
1150000
CY2018Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
4000
CY2017Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
51000
CY2018Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2316000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7871000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
20000
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-33000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1503000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5697000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25742000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20045000
CY2017Q1 us-gaap Interest Paid
InterestPaid
396000
CY2018Q1 xoma Prepaid Financing Cost Related To Issuance Of Common Stock
PrepaidFinancingCostRelatedToIssuanceOfCommonStock
100000
CY2017Q1 xoma Other Receivables Related To Sale Of Property And Equipment
OtherReceivablesRelatedToSaleOfPropertyAndEquipment
811000
CY2018Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of Business </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">XOMA Corporation (referred to as &#8220;XOMA&#8221; or the &#8220;Company&#8221;), a Delaware corporation, has a long history of discovering and developing innovative therapeutics derived from its unique platform of antibody technologies. Over the Company&#8217;s 37-year history, it built an extensive portfolio of fully-funded programs by advancing product candidates into the earlier stages of development and then licensing them to licensees who assumed the responsibilities of later stage development, approval and commercialization. Fully-funded programs are those for which the Company&#8217;s partners pay all of the development and commercialization costs. As licensees advance these programs, the Company is eligible for potential milestone and royalty payments. As part of the Company&#8217;s royalty aggregator business model, the Company intends to expand its portfolio of fully-funded programs by acquiring potential milestone and royalty revenue streams on additional product candidates. </p> <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Financial Condition</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the exception of the year ended December 31, 2017, the Company has typically incurred significant operating losses and negative cash flows from operations since its inception. As of March 31, 2018, the Company had cash and cash equivalents of $42.0 million. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued.</p></div>
CY2017Q4 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
800000
CY2018Q1 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
400000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1416000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000000
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
24800000
CY2018Q1 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.180
CY2018Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2017Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, debt amendments, long-lived assets, restructuring liabilities, legal contingencies, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company&#8217;s billing under government contracts. Under the Company&#8217;s contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), the Company billed using NIH&#8217;s provisional rates and thus is subject to future audits at the discretion of NIAID&#8217;s contracting office. These audits can result in an adjustment to revenue previously reported which potentially could be significant. </p></div>
CY2018Q1 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sale of Future Revenue Streams</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">&#160;<font style="font-size:10pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement.. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</font></p> <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p></div>
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents, such as money market funds. The Company has not encountered any such liquidity issues during 2018. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2018, two partners represented 86% and 13% of total revenues, respectively. For the three months ended March 31, 2017, two partners represented 58% and 42% of total revenues, respectively. As of March 31, 2018, two partners represented 50%<font style="font-size:12pt;"> </font>of the trade receivables balance, respectively<font style="font-size:12pt;">.</font> As of December 31, 2017, one partner represented&nbsp;&nbsp;95% of the trade receivables balance.&nbsp;&nbsp;</p></div>
CY2018Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4500000
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4500000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2017Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2018Q1 us-gaap Contractual Obligation
ContractualObligation
0
CY2017Q1 us-gaap Contractual Obligation
ContractualObligation
0
CY2018Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
35000000
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8600000
CY2017Q1 xoma Proceeds From Sale Of Property Plant And Equipment Including Other Receivables
ProceedsFromSaleOfPropertyPlantAndEquipmentIncludingOtherReceivables
1600000
CY2017Q1 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
300000
CY2018Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
83000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
141000
CY2017Q4 xoma Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
130000
CY2018Q1 xoma Accrued Incentive Compensation
AccruedIncentiveCompensation
90000
CY2017Q4 xoma Accrued Incentive Compensation
AccruedIncentiveCompensation
229000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
237000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
431000
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
754000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
765000
CY2017Q4 xoma Liability Related To Sublease
LiabilityRelatedToSublease
800000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
174000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
179000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6665000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3480000
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17312
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17312
CY2018Q1 xoma Contractual Obligation Estimated Milestone Payments
ContractualObligationEstimatedMilestonePayments
15500000
CY2018Q1 xoma Lessee Leasing Arrangements Operating Leases Expiry Month And Year
LesseeLeasingArrangementsOperatingLeasesExpiryMonthAndYear
2023-04
CY2018Q1 xoma Operating Leases Number Of Successive Renewal Options
OperatingLeasesNumberOfSuccessiveRenewalOptions
2
CY2018Q1 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2017Q4 xoma Subleased Facility Number Of Portions
SubleasedFacilityNumberOfPortions
1
CY2017Q4 xoma Operating Leases Number Of Leased Facilities
OperatingLeasesNumberOfLeasedFacilities
3
CY2017Q4 xoma Operating Leases Sublease Commencement Date
OperatingLeasesSubleaseCommencementDate
2017-12-26
CY2017Q4 xoma Operating Leases Sublease Revenue Receivable
OperatingLeasesSubleaseRevenueReceivable
5100000
CY2017Q4 xoma Operating Leases Sublease Expiry Date
OperatingLeasesSubleaseExpiryDate
2023-04

Files In Submission

Name View Source Status
0001564590-18-012453-index-headers.html Edgar Link pending
0001564590-18-012453-index.html Edgar Link pending
0001564590-18-012453.txt Edgar Link pending
0001564590-18-012453-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xoma-10q_20180331.htm Edgar Link pending
xoma-20180331.xml Edgar Link completed
xoma-20180331.xsd Edgar Link pending
xoma-20180331_cal.xml Edgar Link unprocessable
xoma-20180331_def.xml Edgar Link unprocessable
xoma-20180331_lab.xml Edgar Link unprocessable
xoma-20180331_pre.xml Edgar Link unprocessable
xoma-ex101_237.htm Edgar Link pending
xoma-ex102_238.htm Edgar Link pending
xoma-ex311_18.htm Edgar Link pending
xoma-ex312_17.htm Edgar Link pending
xoma-ex321_6.htm Edgar Link pending